title: [Cost analysis of 3 candins in the treatment of invasive candidiasis in adult non-neutropaenic patients in Spain].
abstract: OBJECTIVE
  To estimate the cost of 3 candins (anidulafungin, caspofungin and micafungin) in the treatment of adult non-neutropaenic patients with invasive candidiasis (IC) in a Spanish hospital pharmacy setting.
  
  
  METHODS
  The overall cost impact was evaluated by varying the percentage dosage required of each candin in different possible scenarios. The prices (in euros) for each presentation were obtained from the Drug Catalogue (in August 2010). Only drug purchase costs were considered. The results are expressed as total cost for each of the 3 candins.
  
  
  RESULTS
  The cost per episode (14 days) of anidulafungin was constant at €5400 per patient. The cost of caspofungin varied from €4281 to €7991, depending on patient weight and liver dysfunction. The cost of micafungin varied from €6000 (100mg/day) to €9000 (when increasing the dose due to inadequate response). Based on a hypothetic cohort of 100 patients with IC, the total cost of anidulafungin treatment would be €540,000, for caspofungin it would be €631,459, and for micafungin it would be €632,998, depending on any dose adjustment required.
  
  
  CONCLUSIONS
  Patients treated with anidulafungin did not require dose adjustment, unlike those treated with caspofungin or micafungin. The use of anidulafungin is a cost-saving treatment for adult non-neutropaenic patients with IC, which would result in better control of the Spanish pharmacy budget.
authors: Departamento de Farmacoeconomía e Investigación de Resultados. Pfizer, Alcobendas, Madrid, España.
authors: M
authors: M
authors: García-Vargas
authors: M A
authors: MA
authors: Casado
authors: N
authors: N
authors: Mir
authors: J A
authors: JA
authors: Barrueta
mesh_terms: D000328:Adult; D000077612:Anidulafungin; D000935:Antifungal Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy* / Q000191:economics*; D000077336:Caspofungin; D003365:Costs and Cost Analysis; D016527:Drug Costs; D054714:Echinocandins / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D055666:Lipopeptides / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D000077551:Micafungin; D010607:Pharmacy Service, Hospital / Q000191:economics; D013030:Spain
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077612:Anidulafungin; D000077336:Caspofungin; D000077551:Micafungin